Comparable population pharmacokinetics and pharmacodynamic breakpoints of cefpirome in cystic fibrosis patients and healthy volunteers

Jurgen Bulitta; Martina Kinzig; Cornelia Landersdorfer; Ulrike Holzgrabe; U Stephan; Fritz Sorgel

doi:10.1128/AAC.01484-10

Comparable population pharmacokinetics and pharmacodynamic breakpoints of cefpirome in cystic fibrosis patients and healthy volunteers

Jurgen Bulitta, Martina Kinzig, Cornelia Landersdorfer, Ulrike Holzgrabe, U Stephan, Fritz Sorgel

Research output: Contribution to journal › Article › Research › peer-review

11 Citations (Scopus)

Abstract

Cystic fibrosis (CF) patients are often reported to have higher clearances and larger volumes of distribution per kilogram of total body weight (WT) for beta-lactams than healthy volunteers. As pharmacokinetic (PK) data on cefpirome from studies of CF patients are lacking, we systematically compared its population PK and pharmacodynamic breakpoints for CF patients and healthy volunteers of similar body size.

Original language	English
Pages (from-to)	2927 - 2936
Number of pages	10
Journal	Antimicrobial Agents and Chemotherapy
Volume	55
Issue number	6
DOIs	https://doi.org/10.1128/AAC.01484-10
Publication status	Published - 2011
Externally published	Yes

Access to Document

10.1128/AAC.01484-10

RM sElocation

Cite this

@article{761c1bbb72c844c7a1ab87b114c93486,

title = "Comparable population pharmacokinetics and pharmacodynamic breakpoints of cefpirome in cystic fibrosis patients and healthy volunteers",

abstract = "Cystic fibrosis (CF) patients are often reported to have higher clearances and larger volumes of distribution per kilogram of total body weight (WT) for beta-lactams than healthy volunteers. As pharmacokinetic (PK) data on cefpirome from studies of CF patients are lacking, we systematically compared its population PK and pharmacodynamic breakpoints for CF patients and healthy volunteers of similar body size.",

author = "Jurgen Bulitta and Martina Kinzig and Cornelia Landersdorfer and Ulrike Holzgrabe and U Stephan and Fritz Sorgel",

year = "2011",

doi = "10.1128/AAC.01484-10",

language = "English",

volume = "55",

pages = "2927 -- 2936",

journal = "Antimicrobial Agents and Chemotherapy",

issn = "1098-6596",

publisher = "American Society for Microbiology",

number = "6",

}

Comparable population pharmacokinetics and pharmacodynamic breakpoints of cefpirome in cystic fibrosis patients and healthy volunteers. / Bulitta, Jurgen; Kinzig, Martina; Landersdorfer, Cornelia; Holzgrabe, Ulrike; Stephan, U; Sorgel, Fritz.

In: Antimicrobial Agents and Chemotherapy, Vol. 55, No. 6, 2011, p. 2927 - 2936.

Research output: Contribution to journal › Article › Research › peer-review

TY - JOUR

T1 - Comparable population pharmacokinetics and pharmacodynamic breakpoints of cefpirome in cystic fibrosis patients and healthy volunteers

AU - Bulitta, Jurgen

AU - Kinzig, Martina

AU - Landersdorfer, Cornelia

AU - Holzgrabe, Ulrike

AU - Stephan, U

AU - Sorgel, Fritz

PY - 2011

Y1 - 2011

N2 - Cystic fibrosis (CF) patients are often reported to have higher clearances and larger volumes of distribution per kilogram of total body weight (WT) for beta-lactams than healthy volunteers. As pharmacokinetic (PK) data on cefpirome from studies of CF patients are lacking, we systematically compared its population PK and pharmacodynamic breakpoints for CF patients and healthy volunteers of similar body size.

AB - Cystic fibrosis (CF) patients are often reported to have higher clearances and larger volumes of distribution per kilogram of total body weight (WT) for beta-lactams than healthy volunteers. As pharmacokinetic (PK) data on cefpirome from studies of CF patients are lacking, we systematically compared its population PK and pharmacodynamic breakpoints for CF patients and healthy volunteers of similar body size.

UR - http://aac.asm.org/content/55/6/2927

U2 - 10.1128/AAC.01484-10

DO - 10.1128/AAC.01484-10

M3 - Article

VL - 55

SP - 2927

EP - 2936

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 1098-6596

IS - 6

ER -